ストックスクリーナーアプリを入手
1.04
5.45%
-0.06
アフターアワーズ：
1.04
前日終値:
$1.10
開ける：
$1.07
24時間の取引高:
1.32M
Relative Volume:
0.55
時価総額：
$94.48M
収益：
-
当期純損益:
$-37.34M
株価収益率:
-0.7647
EPS:
-1.36
ネットキャッシュフロー:
$-36.91M
1週間 パフォーマンス:
-6.31%
1か月 パフォーマンス:
-11.86%
6か月 パフォーマンス:
-17.46%
1年 パフォーマンス:
-19.38%
1日の値動き範囲:
$1.02
$1.10
1週間の範囲:
$1.02
$1.125
52週間の値動き範囲:
$0.772
$1.84
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
名前
Sellas Life Sciences Group Inc
セクター
電話
(646) 200-5278
住所
7 TIMES SQUARE, NEW YORK, NY
SLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.04 | 94.48M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 開始されました | Oppenheimer | Outperform |
| 2018-04-02 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | アップグレード | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc (SLS) 最新ニュース
Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha
Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World
Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView
SELLAS Life Sciences Group Inc. (SLS) reports earnings - Quartz
SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday - Defense World
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update - Defense World
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Drops -2.59% In Early Trade; What Lies Ahead? - Stocks Register
Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN
SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire
3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail
SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq
SELLAS reports promising DLBCL treatment trial results - Investing.com
SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq
SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle
SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News
Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News
SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel
Orangekloud Technology Inc (NASDAQ: ORKT) Up 58.11% From 52-Week Low; YTD Falls -50.99% – Here’s What To Do Now – Marketing Sentinel - Marketing Sentinel
Stock Traders Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - MarketBeat
Insider’s View: Deciphering SELLAS Life Sciences Group Inc (SLS)’s Financial Health Through Ratios - The Dwinnex
Market Analysts see SELLAS Life Sciences Group Inc [SLS] gaining to $18. Time to buy? - The DBT News
SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - Defense World
You Should Read This Analysis Before Investing in SELLAS Life Sciences Group Inc (NASDAQ:SLS) - US Post News
Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World
Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register
SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow
SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa
SELLAS secures $25 million in registered direct offering - MSN
SELLAS Life Sciences Group Announces $25 Million Registered - GlobeNewswire
Major Healthcare Investor Backs SELLAS with $25M DealHere's the Full Structure - StockTitan
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - Defense World
SELLAS Life Sciences Announces Positive Phase 3 Trial Results - TipRanks
SELLAS Life Sciences stock falls on GPS data (SLS:NASDAQ) - Seeking Alpha
SELLAS Life Sciences Announces Positive Outcome of Interim - GlobeNewswire
SELLAS Phase 3 AML Trial Shows Promising 13.5-Month Survival Data, Double Historical Average - StockTitan
Sellas Life Sciences Group Inc (SLS) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):